Gilead Sciences
GILD
About: Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
Employees: 17,600
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
34% more call options, than puts
Call options by funds: $1.41B | Put options by funds: $1.06B
23% more first-time investments, than exits
New positions opened: 184 | Existing positions closed: 149
13% more repeat investments, than reductions
Existing positions increased: 821 | Existing positions reduced: 725
2.45% more ownership
Funds ownership: 83.67% [Q1] → 86.12% (+2.45%) [Q2]
2% more capital invested
Capital invested by funds: $117B [Q1] → $119B (+$2B) [Q2]
0% more funds holding
Funds holding: 1,984 [Q1] → 1,986 (+2) [Q2]
35% less funds holding in top 10
Funds holding in top 10: 51 [Q1] → 33 (-18) [Q2]
Research analyst outlook
5 Wall Street Analysts provided 1 year price targets over the past 3 months
5 analyst ratings
|
JP Morgan
Chris Schott
|
$145
|
Overweight
Maintained
|
16 Sep 2025 |
|
RBC Capital
Brian Abrahams
|
$98
|
Sector Perform
Maintained
|
8 Aug 2025 |
|
UBS
Colin Bristow
|
$112
|
Neutral
Maintained
|
8 Aug 2025 |
|
Truist Securities
Asthika Goonewardene
|
$127
|
Buy
Upgraded
|
8 Aug 2025 |
|
Needham
Joseph Stringer
|
$133
|
Buy
Upgraded
|
25 Jul 2025 |
Financial journalist opinion
Based on 28 articles about GILD published over the past 30 days
